Repligen Corporation (RGEN)

Repligen Corp. experienced several stock-related events over the past six months. In Q3 2025, the company reported strong financial results and raised its full-year revenue guidance. Repligen launched new high-performance chromatography resins. In Q4 2025, the company reported revenue growth and provided initial guidance for 2026. There were reports of oversold conditions, but analysts gave RGEN a moderate buy recommendation. Repligen's Board elected Martin Madaus as Chair.

Repligen Corp. experiences a normal seasonality split in demand, with approximately 48% of its revenue expected in the first half of the year. While there is generally strong demand, the company has noted a more pronounced gene therapy headwind in the first half of 2026. Repligen has also observed positive order momentum, with orders outpacing revenue, particularly in Filtration and Analytics.

Repligen Corporation is a global life sciences company focused on developing and commercializing bioprocessing technologies and systems to enhance the manufacturing of biological drugs. The company operates in the life sciences sector, specifically within the biotechnology, pharmaceutical, and medical devices industries, providing essential tools and systems for the bioprocessing industry. Repligen's major products and services include filtration and fluid management systems, chromatography systems and resins, process analytics tools, proteins and ligands, and custom bioprocessing solutions.

Repligen Corporation has a global presence with its headquarters in Waltham, Massachusetts. The company operates across 22 sites globally, with manufacturing facilities and offices in the United States, Europe, and Asia Pacific, serving a worldwide customer base.

Repligen has maintained a strong brand reputation due to its focus on innovation and strategic expansion within the bioprocessing industry. The company has launched new products, made strategic acquisitions, reported robust financial results, and focused on supporting the manufacturing of new therapeutic modalities. There is no readily available information indicating any significant negative events that have adversely affected Repligen Corp.'s brand reputation in the past year.

Institutional investors hold a substantial majority of Repligen's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Price T Rowe Associates Inc. Individual and retail investors also constitute a portion of the shareholder base, though insider ownership remains a small percentage of total shares.